A Phase 2 interventional study of Natalizumab and Placebo in Epilepsy, Focal Seizures, Partial Seizures, sponsored by Biogen. Completed at 31 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-14.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.
Among the 793 studies in Epilepsy with a site in United States, this one is the 224th largest by enrollment of the 588 interventional ones that give a count, is one of 44 that started in 2018, is one of 103 in phase 2, and was the 451st registered.
1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Cadence Neuroscience · Sites in United States
Ages 7+ · Men only
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Epilepsy studies recruiting now, 112 (39%) set no upper age limit and 149 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
793 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 126 · Phase 3 133 · Phase 4 51
First in 1975; this study’s year is marked. 44 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 40 across the 588 interventional studies, 90 across the 193 observational. Of the 526 that completed or were terminated, 243 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 793 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 1 study filed under Epilepsy — fewer than ten, so there is no comparison to draw.
72 of the studies in Epilepsy with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07010471Phase 3Praxis Precision MedicinesA Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05431595Phase 3M.D. Anderson Cancer CenterManaging Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | 2027-02-02 |
Add all 72 to your calendar (.ics) → With an account.
Among the 793 studies in Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE; Other protocol defined Inclusion/Exclusion criteria may apply
Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
Drug: Natalizumab
Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
Other: Placebo
As specified in the treatment arm.
Also known as: Tysabri
As specified in treatment arms.
Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment
Seizures included were focal aware seizures with motor signs, focal impaired awareness seizures and focal to bilateral tonic-clonic seizure. Focal aware seizures without motor signs were not included. Seizure clusters (where individual seizures cannot be distinguished) were counted as 1 seizure per cluster on each day that they are present. Study baseline seizure frequency (number of seizures per 28 days) was calculated based on participant's seizure diary data during prospective baseline phase. Seizure frequency (SF) at post baseline visit was calculated based on sum of the seizures reported in participant seizure diary and the number of days with non-missing SF data in participant seizure diary on or after the previous visit date. Change from Baseline are based on natural log transformation of baseline SF or SF at post baseline visit correspondingly. For log-transformation, the quantity 0.2 {ln(x+0.2)} was added to the SF at post baseline visit to account for 0 seizure count.
Time frame: Baseline, Week 8 to Week 24
Percentage of Responders During Weeks 8 to 24 of Treatment
Responders were defined as participants with \>=50% reduction from study baseline in seizure frequency during Weeks 8 to 24. Study baseline seizure frequency (number of seizures per 28 days) was calculated based on participants' seizure diary data during the prospective Baseline Phase (number of seizures during Baseline Phase/number of days with non-missing seizure frequency\*28). Participants who withdrew from treatment or required protocol specified modifications of antiepileptic drug (AEDs) prior to Week 24 (completion of the Placebo-controlled Phase) or death related to Epilepsy were considered as non-responders in the analysis. Seizure frequency at post baseline visit was calculated based on the sum of the seizures reported in the subject seizure diary and the number of days with non-missing seizure frequency data in the subject seizure diary on or after the previous visit date.
Time frame: Week 8 to Week 24
Number of Participants Free From Seizures During Weeks 8 to 24 of Treatment
Seizure free is defined as a participant with no seizure reported and no missing diary during Weeks 8 to 24. Participants who withdrew from treatment, required modifications of AEDs prior to Week 24 (completion of the Placebo-controlled Phase), or any missing diary data during Weeks 8 to 24 of treatment were not considered as seizure free in the analysis.
Time frame: Week 8 to Week 24
Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment
Study baseline seizure free days (number of seizure free days per 28 days) was calculated based on the diary data during the prospective baseline Phase (Number of seizures during baseline Phase/Number of days with non-missing seizure frequency\*28). Seizure frequency at post baseline visit was calculated based on the sum of the seizures reported in the subject seizure diary and the number of days with non-missing seizure frequency data in the subject seizure diary on or after the previous visit date.
Time frame: Baseline, Week 8, Week 12, Week 16, Week 20, Week 24
Percentage of Participants With Inadequate Treatment Response During Weeks 8 to 24 of Treatment
Inadequate treatment response includes participants who withdraw from treatment due to lack of efficacy or require protocol specified modifications of antiepileptic drugs (AEDs) prior to Week 24 (completion of the placebo- controlled phase) or death related to Epilepsy.
Time frame: Week 8 to Week 24
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect.
Time frame: From first dose up to 24 weeks after the last dose of study treatment (up to Week 68)
Number of Participants With Clinically Significant Laboratory Abnormalities
The laboratory assessments included hematology, blood chemistry, serology, urinalysis and vital signs assessment.
Time frame: From first dose up to 16 weeks after the last dose of study treatment (up to Week 60)
Number of Participants With Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) or C-SSRS Score
C-SSRS is a prospective assessment tool to evaluate suicidal ideation and behavior. C-SSRS score for suicidal ideation ranges from 1 to 10, where 1=Wish to be Dead; 2=Nonspecific Active Suicidal Thoughts; 3=Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4=Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5=Active Suicidal Ideation with Specific Plan and Intent; and for suicidal behavior ranges from 6=Preparatory Acts or Behavior, 7=Aborted Attempt, 8=Interrupted Attempt, 9=Actual Attempt (nonfatal), 10=Completed Suicide. Participants with a C-SSRS score between 1-10 are reported in this outcome measure.
Time frame: Placebo-controlled Phase: Baseline, Weeks 4, 8, 12, 16, 20 and 24; Open-label Phase: Baseline, Weeks 28, 32, 36, 40, 44, 48 and 60/End of Study (EOS)
Participants were enrolled at 31 investigational sites in United States from 20 March 2018 to 18 Nov 2020.
| Milestone | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| Started | 34 | 33 | 0 | 0 |
| Number of participants dosed | 34 | 32 | 0 | 0 |
| Completed | 31 | 30 | 0 | 0 |
| Not completed | 3 | 3 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| Withdrew: Participants did not receive study drug | 0 | 1 | 0 | 0 |
| Milestone | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| Started | 0 | 0 | 31 | 30 |
| Completed | 0 | 0 | 27 | 29 |
| Not completed | 0 | 0 | 4 | 1 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
Seizures included were focal aware seizures with motor signs, focal impaired awareness seizures and focal to bilateral tonic-clonic seizure. Focal aware seizures without motor signs were not included. Seizure clusters (where individual seizures cannot be distinguished) were counted as 1 seizure per cluster on each day that they are present. Study baseline seizure frequency (number of seizures per 28 days) was calculated based on participant's seizure diary data during prospective baseline phase. Seizure frequency (SF) at post baseline visit was calculated based on sum of the seizures reported in participant seizure diary and the number of days with non-missing SF data in participant seizure diary on or after the previous visit date. Change from Baseline are based on natural log transformation of baseline SF or SF at post baseline visit correspondingly. For log-transformation, the quantity 0.2 {ln(x+0.2)} was added to the SF at post baseline visit to account for 0 seizure count.
| log(seizure/28 days) | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) |
|---|---|---|
| Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment | -0.43 ± 0.162 | -0.58 ± 0.165 |
Responders were defined as participants with \>=50% reduction from study baseline in seizure frequency during Weeks 8 to 24. Study baseline seizure frequency (number of seizures per 28 days) was calculated based on participants' seizure diary data during the prospective Baseline Phase (number of seizures during Baseline Phase/number of days with non-missing seizure frequency\*28). Participants who withdrew from treatment or required protocol specified modifications of antiepileptic drug (AEDs) prior to Week 24 (completion of the Placebo-controlled Phase) or death related to Epilepsy were considered as non-responders in the analysis. Seizure frequency at post baseline visit was calculated based on the sum of the seizures reported in the subject seizure diary and the number of days with non-missing seizure frequency data in the subject seizure diary on or after the previous visit date.
| percentage of responders | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) |
|---|---|---|
| Percentage of Responders During Weeks 8 to 24 of Treatment | 17.6 | 31.3 |
Seizure free is defined as a participant with no seizure reported and no missing diary during Weeks 8 to 24. Participants who withdrew from treatment, required modifications of AEDs prior to Week 24 (completion of the Placebo-controlled Phase), or any missing diary data during Weeks 8 to 24 of treatment were not considered as seizure free in the analysis.
| Participants | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) |
|---|---|---|
| Number of Participants Free From Seizures During Weeks 8 to 24 of Treatment | 1 | 0 |
Study baseline seizure free days (number of seizure free days per 28 days) was calculated based on the diary data during the prospective baseline Phase (Number of seizures during baseline Phase/Number of days with non-missing seizure frequency\*28). Seizure frequency at post baseline visit was calculated based on the sum of the seizures reported in the subject seizure diary and the number of days with non-missing seizure frequency data in the subject seizure diary on or after the previous visit date.
| percent change | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) |
|---|---|---|
| Baseline | 16.23 ± 7.347 | 17.54 ± 7.223 |
| Week 8 | 4.33 ± 50.740 | 39.23 ± 130.988 |
| Week 12 | 2.41 ± 52.613 | 32.59 ± 104.775 |
| Week 16 | -0.40 ± 43.380 | 44.04 ± 153.714 |
| Week 20 | 18.48 ± 101.318 | 40.44 ± 144.768 |
| Week 24 | 4.27 ± 47.125 | 33.92 ± 114.436 |
Inadequate treatment response includes participants who withdraw from treatment due to lack of efficacy or require protocol specified modifications of antiepileptic drugs (AEDs) prior to Week 24 (completion of the placebo- controlled phase) or death related to Epilepsy.
| percentage of participants | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) |
|---|---|---|
| Percentage of Participants With Inadequate Treatment Response During Weeks 8 to 24 of Treatment | 6 | 3 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect.
| Participants | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| AEs | 22 | 24 | 20 | 17 |
| SAEs | 1 | 1 | 3 | 2 |
The laboratory assessments included hematology, blood chemistry, serology, urinalysis and vital signs assessment.
| Participants | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities | 0 | 0 | 0 | 0 |
C-SSRS is a prospective assessment tool to evaluate suicidal ideation and behavior. C-SSRS score for suicidal ideation ranges from 1 to 10, where 1=Wish to be Dead; 2=Nonspecific Active Suicidal Thoughts; 3=Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; 4=Active Suicidal Ideation with Some Intent to Act, without Specific Plan; 5=Active Suicidal Ideation with Specific Plan and Intent; and for suicidal behavior ranges from 6=Preparatory Acts or Behavior, 7=Aborted Attempt, 8=Interrupted Attempt, 9=Actual Attempt (nonfatal), 10=Completed Suicide. Participants with a C-SSRS score between 1-10 are reported in this outcome measure.
| Participants | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| Baseline: Suicidal Ideation or Behavior (1-10) | 0 | 1 | 1 | 1 |
| Week 4: Suicidal Ideation or Behavior (1-10) | 0 | 0 | — | — |
| Week 8: Suicidal Ideation or Behavior (1-10) | 0 | 0 | — | — |
| Week 12: Suicidal Ideation or Behavior (1-10) | 0 | 1 | — | — |
| Week 16: Suicidal Ideation or Behavior (1-10) | 0 | 3 | — | — |
| Week 20: Suicidal Ideation or Behavior (1-10) | 1 | 2 | — | — |
| Week 24: Suicidal Ideation or Behavior (1-10) | 1 | 2 | — | — |
| Week 28: Suicidal Ideation or Behavior (1-10) | — | — | 3 | 2 |
| Week 32: Suicidal Ideation or Behavior (1-10) | — | — | 1 | 2 |
| Week 36: Suicidal Ideation or Behavior (1-10) | — | — | 1 | 1 |
| Week 40: Suicidal Ideation or Behavior (1-10) | — | — | 1 | 2 |
| Week 44: Suicidal Ideation or Behavior (1-10) | — | — | 1 | 2 |
| Week 48: Suicidal Ideation or Behavior (1-10) | — | — | 1 | 2 |
| Week 60/End of Study (EOS): Suicidal Ideation or Behavior (1-10) | — | — | 0 | 2 |
Collected over From first dose up to 24 weeks after the last dose of study treatment (up to Week 68). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Placebo-controlled Phase) | 0/34 (0%) | 1/34 (2.9%) | 15/34 (44.1%) |
| Natalizumab 300 mg (Placebo- Controlled Phase) | 0/32 (0%) | 1/32 (3.1%) | 17/32 (53.1%) |
| Placebo to Natalizumab 300 mg (Open-label Phase) | 0/31 (0%) | 3/31 (9.7%) | 13/31 (41.9%) |
| Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) | 0/30 (0%) | 2/30 (6.7%) | 9/30 (30%) |
| Event | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo- Controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| SeizureNervous system disorders | 1/34 | 1/32 | 1/31 | 1/30 |
| Large intestine perforationGastrointestinal disorders | 0/34 | 0/32 | 0/31 | 1/30 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/34 | 0/32 | 0/31 | 1/30 |
| Seizure clusterNervous system disorders | 0/34 | 0/32 | 1/31 | 0/30 |
| COVID-19Infections and infestations | 0/34 | 0/32 | 1/31 | 0/30 |
| Event | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo- Controlled Phase) | Placebo to Natalizumab 300 mg (Open-label Phase) | Natalizumab 300 mg to Natalizumab 300 mg (Open-label Phase) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/34 | 6/32 | 3/31 | 3/30 |
| DizzinessNervous system disorders | 1/34 | 5/32 | 1/31 | 2/30 |
| FallInjury, poisoning and procedural complications | 2/34 | 4/32 | 2/31 | 3/30 |
| Chest discomfortGeneral disorders | 0/34 | 0/32 | 3/31 | 0/30 |
| NauseaGastrointestinal disorders | 1/34 | 3/32 | 0/31 | 2/30 |
| Back painMusculoskeletal and connective tissue disorders | 3/34 | 2/32 | 0/31 | 1/30 |
| SomnolenceNervous system disorders | 3/34 | 0/32 | 0/31 | 0/30 |
| FlushingVascular disorders | 3/34 | 0/32 | 0/31 | 0/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/34 | 2/32 | 1/31 | 2/30 |
| Dental cariesGastrointestinal disorders | 0/34 | 0/32 | 0/31 | 2/30 |
The Intent to Treat (ITT) population is defined as all participants who were randomized and received any dose of study treatment. Ethnicity was not collected in this study.
| Age, Continuous(years) | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Total |
|---|---|---|---|
| Mean | 39.1 ± 12.17 | 42.8 ± 14.56 | 40.9 ± 13.41 |
| Sex: Female, Male(Participants) | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 18 | 18 | 36 |
| Race (NIH/OMB)(Participants) | Placebo (Placebo-controlled Phase) | Natalizumab 300 mg (Placebo-controlled Phase) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 8 | 7 | 15 |
| White | 19 | 23 | 42 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Jan 2020, 21 months.
Results were first posted in Apr 2021, 1 year 3 months after primary completion.
Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 21 months is close to that.
Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Natalizumab